Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.50 |
| ▸ | FNTB | P49356 | 8/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4376775 | 0.82 | FNTA (0.46) | FNTAFNTBIDO1PGGT1BMAPK1 | |
| SCHEMBL4377478 | 0.81 | FNTA (0.45) | FNTAFNTBMAPK1 | |
| SCHEMBL4382960 | 0.79 | FNTA (0.52) | FNTAFNTBIDO1PGGT1BMAPK1 | |
| SCHEMBL5960985 | 0.77 | RORC (0.52) | FNTAFNTB | |
| SCHEMBL4378944 | 0.77 | FNTA (0.49) | FNTAFNTBIDO1PGGT1B | |
| SCHEMBL5089019 | 0.70 | HRH3 (0.43) | FNTAFNTBIDO1TDO2PGGT1B | |
| SCHEMBL5778239 | 0.68 | FNTA (0.68) | FNTAFNTBIDO1PGGT1B | |
| SCHEMBL31016250 | 0.68 | SMN1; SMN2 (0.42) | IDO1TDO2MAPK1 | |
| SCHEMBL31016248 | 0.68 | SMN1; SMN2 (0.42) | IDO1TDO2MAPK1 | |
| SCHEMBL13013180 | 0.68 | CA1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339709-B1 | FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-24 | — | — | EP | disclosed |
| US-7153958-B2 | Farnesyl transferase inhibiting benzoheterocyclic derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-26 | — | — | US | disclosed |
| US-20040034218-A1 | Farnesyl transferase inhibiting benzoheterocyclic derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-19 | — | — | US | disclosed |
| EP-1339709-A1 | FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042296-A1 | FARNESYL TRANSFERASE INHIBITING BENZOHETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034218-A1 | Farnesyl transferase inhibiting benzoheterocyclic derivatives | FNTA, FNTB, RCE1 | FNTA 1/4885FNTB 2/4885IDO1 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.